SEC Filings

SEC Filings
Home / SEC Filings

SEC Filings

8-K
PROTALIX BIOTHERAPEUTICS, INC. filed this Form 8-K on 08/09/2018
Entire Document
 

 

 

PROTALIX BIOTHERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(U.S. dollars in thousands, except share and per share data)
(Unaudited)

 

 

   Six Months Ended   Three Months Ended 
   June 30, 2018   June 30, 2017   June 30, 2018   June 30, 2017 
REVENUES   $6,559   $9,247   $2,006   $6,358 
COST OF REVENUES    (5,107)   (7,611)   (2,183)   (5,523)
GROSS PROFIT (LOSS)    1,452    1,636    (177)   835 
RESEARCH AND DEVELOPMENT EXPENSES (1)    (14,762)   (15,271)   (7,476)   (9,304)
Less – grants    1,078    1,816    235    478 
RESEARCH AND DEVELOPMENT EXPENSES, NET    (13,684)   (13,455)   (7,241)   (8,826)
SELLING, GENERAL AND ADMINISTRATIVE
EXPENSES (2)
   (4,656)   (5,351)   (2,158)   (2,814)
OPERATING LOSS    (16,888)   (17,170)   (9,576)   (10,805)
FINANCIAL EXPENSES    (4,013)   (5,132)   (1,793)   (3,045)
FINANCIAL INCOME    207    1,665    75    40 
(LOSS) INCOME FROM CHANGE IN FAIR VALUE OF
CONVERTIBLE NOTES EMBEDDED DERIVATIVE
        (38,061)        14,260 
FINANCIAL (EXPENSES) INCOME, NET    (3,806)   (41,528)   (1,718)   11,255 
NET (LOSS) INCOME FOR THE PERIOD   $(20,694)  $(58,698)  $(11,294)  $450 
NET (LOSS) EARNINGS PER SHARE OF COMMON STOCK :                    
BASIC                    
Net (loss) earnings per share of common stock  $(0.14)  $(0.47)  $(0.08)  $0.00 
DILUTED                    
Net loss per share of common stock   $(0.14)  $(0.47)  $(0.08)  $(0.06)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING (LOSS) EARNINGS PER SHARE                    
BASIC    145,985,445    126,000,782    146,644,450    127,523,706 
DILUTED   145,985,445    126,000,782    146,644,450    192,598,389 
(1) Includes share-based compensation   $40   $120   $(2)  $55 
(2) Includes share-based compensation   $34   $96   $14   $43